Brooks Laboratories (BROOKS.NS) Osake Kurssi

Brooks Laboratories Ltd is a pharmaceutical manufacturing enterprise headquartered in Mumbai, Maharashtra, India, operating within the health care sector under the industry classification of life sciences tools and services. The company maintains a workforce of 296 full-time employees dedicated to its research and development initiatives and production operations. Brooks Laboratories went public on September 2, 2011, listing its shares on the National Stock Exchange of India under the ticker symbol BROOKS.NS and the ISIN INE650L01011. The firm’s primary business activity revolves around the Pharmaceuticals segment, where it focuses on the manufacturing of a diverse range of pharmaceutical dosage forms. These products include injections, tablets, dry syrups, and eye and ear drops, catering to various therapeutic needs. A significant portion of the company’s portfolio consists of products under the Carbapenem category, which includes several specific formulations such as Imipenem combined with Cilastatin in 250mg and 500mg strengths, as well as Meropenem in dosages ranging from 125mg to 1000mg. The Meropenem offerings also include combinations with Sulbactam and Tazobactam, alongside Doripenem in 500mg and 1000mg strengths. In addition to Carbapenems, Brooks Laboratories produces Penicillins available in injection, tablet, and dry syrup forms. The General category of its product line encompasses liquid injections, dry powder injections, and ophthalmic and otic drops. Notable liquid injections include Iron sucrose with a concentration of 100mg/5ml. The company’s manufacturing infrastructure includes plants located in Baddi, Himachal Pradesh. Brooks Laboratories markets its pharmaceutical products both nationally and internationally, supplying to various regulated markets around the world. The company’s operational scope is defined by its commitment to producing high-quality pharmaceuticals that meet international regulatory standards. Through its dedicated team and established manufacturing facilities, Brooks Laboratories continues to serve the global health care market with its extensive range of medicinal products. The firm’s online presence is maintained through its official website, providing further information on its products and services. As a listed entity, the company is subject to the regulatory requirements of the Indian stock markets, ensuring transparency and accountability in its corporate governance and financial reporting.